8-K - Fate Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Management Change

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) On Octobe

Management Change

$495.0KChief Financial Officer of the CompanyCompany on any matter relating to the Company

7.01

and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Offer Letter between the Company and Kamal Adawi, dated as of October 13, 2025 99.

Exhibits Only

Source Document

Exhibits (3)

10.1

EX-10.1

8-K

99.1

EX-99.1